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PREVENTION OF IDIOPATHIC PNEUMONIA SYNDROME BY INTRA-BONE
MARROW INJECTION OF DONOR CELLS
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Kadohisa, S.1, Kondo, E.1, Shinagawa, K.1, Mominoki, K.2, Kanekura, T.3,
Tanimoto, M.1, Maeda, Y.1 1Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; 2Ad-
vanced Science Research Center, Okayama University, Okayama, Japan;
3Kagoshima University Graduate School of Medical and Dental Sciences,
Kagoshima, Japan
Intra-bone marrow (IBM) stem cell transplant (SCT) technique
has been recently developed and several clinical and experimental
studies reported that IBM-SCT is associated with high rate of en-
graftment and low incidence of acute GVHD. Idiopathic pneumonia
syndrome (IPS) is a significant cause ofmortality and remains amajor
obstacle after allogeneic SCT. In the present study, the extent of IPS
after IBM-SCT was compared with that after conventional intrave-
nous SCT (IV- SCT) by using a lethally irradiated B6(H-2b) into F1
(H-2b/d) mouse IPS model. IBM-SCT showed significantly im-
proved the clinical GVHD score and reduced total cells and
CD3+Tcells in bronchoalveolar lavage fluid compared with IV-
SCT (p \ 0.05). Histopathological examination of the lung at 6
weeks post SCT showed significantly reduced IPS pathology in re-
cipients of IBM-SCT(p\0.05). Recipient mice were imaged at dif-
ferent times, ranging from 1 hour to 3 days using a lethally irradiated
luciferase expressing transgenic FVB/N (H-2q) into BALB/c (H-2d)
mouse model. The majority of injected donor cells were trapped in
the lung one hour after IV- SCT. In contrast, significant fewer cells
were localized in the lung after IBM-SCT (2.07 vs. 6.30 x 106 pho-
tons/sec/animal, p\ 0.01). Although donor cells decreased in the
lung 2 to 3 hours after SCT, continued increase in donor cells
occurred in the lung from 6 hours to 3days after both IV and
IBM- SCT. Significantly more donor cells detected in the lung
from 6 hours to 3days after IV- SCT compared with that after
IBM-SCT (p\0.001). Taken together, IBM-SCT reduces trapping
of injected donor cells in the lung and ameliorates IPS after alloge-
neic SCT. Targeting donor cells trafficking in the lung may be
a promising strategy for preventing IPS.472
PLASMA CYTOKINE CONCENTRATIONS ACCORDING TO CHRONIC GVHD
SUBTYPE
Murase, T.1, Lee, S.J.2, Kurland, B.3, Chai, X.3, Hansen, J.A.2,
Flowers, M.E.D.2, Onizuka, M.4, Toyosaki, M.4, Inoko, H.5, Ando, K.4
1Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan; 2Fred
Hutchinson Cancer Research Center, Seattle,WA; 3FredHutchinson Can-
cer Research Center, Seattle, WA; 4Tokai University, Isehara, Kanagawa,
Japan; 5Tokai University, Isehara, Kanagawa, Japan
Finding biomarkers for the phenotype and activity of chronic
GVHD (cGVHD) may improve understanding of the disease and
allow tailored therapy. We examined plasma levels of cytokines in
hematopoietic cell transplant (HCT) recipients, comparing levels
of patients with and without cGVHD, and among 3 clinical cGVHD
subgroups.
Methods: Using 867 assessments for 336 individual cGVHD pa-
tients from 6 centers in the Chronic GVHD Consortium, k-means
hierarchical clustering identified three clinical subtypes of cGVHD
based on the Lee symptom scale, a self-report cGVHD measure
with 7 subscales. Plasma samples were selected from a single center
(Fred Hutchinson Cancer Research Center) as archetypes for the 3
cGVHD subtypes: 1) high symptoms (‘High’, n5 20), 2) high symp-
toms but without oral or GImanifestations (‘High, not mouth/GI’, n
5 20), 3) low symptoms (‘Low’, n 5 20). Samples obtained from
HCT recipients without cGVHD served as controls (n5 10). Six ad-
ditional cGVHD samples that were not easily classified into a clinical
phenotype were included in the cGVHD vs. no cGVHD analysis
only. Plasma levels of IL-4, IL-5, IL-6, IL-8, IL-10, IL-17A,
IL-17F, IFN-gamma, MCP-1, TNFR-II, and TGFb1, 2, 3 were
measured using standardized Luminex assays. TGFb3 results wereexcluded for technical reasons. Plasma BAFF levels were measured
by ELISA. Linear regression models compared log-transformed
cytokine levels for cGVHD versus control, and between cGVHD
subtypes, controlling for plate effects.
Results: Median TNFR-II levels were estimated at 54% higher in
cGVHD patients compared to controls (ratio1.54, 95% CI 1.13-
2.09, p5 0.007) but did not differ among cGVHD subtypes. Several
other cytokines (TGFb1, TGFb2, IL-17F and IL-17A) had 0.01\p
\ 0.05 in specific comparisons but should be interpreted cautiously
because of multiple testing. Other cytokines were not found to differ
between cGVHD and controls or among 3 cGVHD subtypes.
Conclusions: TNFR-II was higher in cGVHD than patients
without cGVHD. These preliminary results did not confirm other
putative cGVHD biomarkers reported by others.
High vs. High, High, not High vs. cGVHD vs.
not mouth/GI mouth/ GI vs. Low Low ControlCytokine n
ratio*
(p-value)
ratio*
(p-value)
ratio*
(p-value)
ratio*
(p-value)IL_4 76 0.84 (—) 1.14 (—) 0.96 (—) 1.01 (—)
IL_5 76 0.81 (—) 1.06 (—) 0.86 (—) 1.03 (—)
IL_6** 47 0.82 (—) 0.83 (—) 0.68 (—) 1.01 (—)
IL_8 76 0.91 (—) 0.90 (—) 0.82 (—) 1.28 (—)
IL_10 76 0.90 (—) 0.99 (—) 0.89 (—) 1.30 (—)
IL_17A 76 0.81 (—) 1.12 (—) 0.92 (—) 1.56 (0.04)
IL_17F 76 0.92 (—) 0.90 (—) 0.83 (0.04) 1.05 (—)
IFNg 76 0.88 (—) 0.98 (—) 0.86 (—) 1.07 (—)MCP_1 76 0.89 (—) 1.02 (—) 0.90 (—) 1.19 (—)
sTNFR_II 76 1.15 (—) 1.03 (—) 1.18 (—) 1.54 (0.007)
TGFb1 76 0.62 (0.10) 2.00 (0.02) 1.23 (—) 1.08 (—)
TGFb2 75 0.56 (0.08) 2.21 (0.02) 1.25 (—) 1.35 (—)
BAFF 76 1.11 (—) 0.86 (—) 0.96 (—) 1.12 (—)*Ratio of median estimated concentration for first group over median
for second group. (Group comparisons are ratios due to the log trans-
formation of cytokine concentrations in regression models.)
**Concentrations on one plate were below the assay limit of detection.
– p > 0.10.473
ADOPTIVELY TRANSFERRED NK CELLS HOME TO TUMOR SITES AND
ACCUMULATE WITH TUMOR GROWTH BUT DO NOT LEAD TO TUMOR
REGRESSION IN A MURINE B-CELL LYMPHOMA MODEL
Gill, S.1, Florek, M.1, Kohrt, H.E.2, Negrin, R.S.1 1Stanford University,
Stanford, CA; 2Stanford University, Stanford, CA
Introduction: Natural killer (NK) cells can reject tumor in in vitro
cytotoxicity experiments and in murine models where depletion of
endogenous NK cells leads to accelerated tumor growth. Given
that allogeneic NK cells can be safely transferred into mice and
humans, it is now important to investigate whether these NK cells
can home to tumor.
Methods: A20 B-cell lymphoma cells (1 x 10^6) were injected
subcutaneously into BalbC recipients at the same time as total
body irradiation and a T-cell depleted bone marrow transplant
from MHC-mismatched wild-type FVB donors. Once the tumor
became palpable (10-14 days), mice were injected intravenously
with 0.5 x 10^6 fresh NK cells derived from luciferase-trans-
genic (Luc+) FVB donors. Some animals received intraperito-
neal rhIL-2. Tumor growth was monitored by regular caliper
measurements and NK cell trafficking was evaluated by biolumi-
nescent imaging (BLI). Animals were sacrificed when the tumor
began to ulcerate, and the tumor mass as well as control tissues
were harvested for immune cell phenotyping and functional
studies.
Results:NK cells infused into control non-tumor bearing animals
homed to lymph nodes, spleen and liver with a maximal BLI signal
at the end of the second week as previously shown (Olson et al,
J Immunol 2009) By contrast, in tumor bearing-animals the Luc+
NK cells homed to lymphoid organs in the first week, followedS323
S324 Poster Session IIby progressive localization of the BLI signal to the tumor site. The
accumulation of NK cells increased with increasing tumor size,
such that the BLI signal of NK cells from the tumor bed repre-
sented approximately 30% of the total animal BLI. Survival advan-
tage was not observed in animals receiving NK cells, regardless of
the administration of IL-2. The tumor microenvironment (TME)
contained a network of Treg cells as well as conventional and plas-
macytoid dendritic cells, most of which were donor bone-marrow
derived and were markedly increased when compared with control
tissues (Tregs 40% vs 8%, p5 0.0034; cDC 30% vs 6%, p5 0.02).
Donor NK cells reisolated from the tumor showed a trend to re-
duced activation by CD69 expression (3% compared with 24%
in normal spleen, p5 0.09), and similarly had impaired production
of interferon-gamma upon restimulation.
Conclusions: Adoptively transferred allogeneic NK cells home to
tumor, showing a striking and paradoxical accumulation with in-
creasing tumor size. These NK are de-activated, possibly due to ex-
posure to the immunosuppressive TME.474
SEQUENTIAL GENE EXPRESSION ANALYSIS DURING THE EARLY ALLOR-
EACTIVE PHENOMENA AFTER ALLOGENEIC BMT IDENTIFIES GENE SETS
AND PATHWAYS DIFFERENTIALLY EXPRESSED IN THE SKIN AND THE
BLOOD OF BMT RECIPIENTS: IMPLICATIONS FOR THE DISCOVERY OF
BIOMARKERS OF CUTANEOUS GVHD THAT ARE RELEVANT TO THE
TARGET ORGAN
Duarte,R.F.1,Garcia-Gutierrez, J.V.3, Sanchez-Ortega, I.1,Remigia,M.J.2,
Rodriguez, M.E.4, Pati~no, B.1, Mataix, A.2, Fleta, B.3, Martinez, N.4,
Odriozola, J.3, Solano, C.2, Sanchez-Beato, M.4 1Catalan Institute of Oncol-
ogy, Barcelona, Barcelona, Spain; 2Hospital Clınico Universitario, Valencia,
Valencia, Spain; 3Hospital Ramon y Cajal,Madrid,Madrid, Spain; 4Spanish
National Cancer Research Centre, Madrid, Madrid, Spain
Our understanding of the alloreactive phenomena that follow
allogeneic BMT (alloBMT) and lead to GVHD in target organs
comes essentially from animal models. In humans, the use of tar-
get tissues has been largely limited to diagnostic purposes, while
the study of immunological pathways and biomarkers of GVHD
has been performed in peripheral blood (PB) or urine. Hence,
we decided to collect prospectively and in parallel skin biopsies
and PB samples before and after alloBMT in order to investigate
sequential changes in alloreactive phenomena and biomarkers that
are relevant to the skin as a target organ of GVHD. Sixty-five
adult recipients of alloBMT for hematological malignancies (38
male; age 49, 21-67; 38 reduced intensity; 40 related donor) had
PB and skin biopsies taken pretransplant and on days 0, +14-21,
+100 and at the start of GVHD. A high-throughput discovery-
driven strategy was carried out using Agilent Whole Genome Mi-
croarrays on RNA from PBMCs and snap-frozen skin extracted
with TRIZOL and amplified with RNA ampULSe. Gene expres-
sion data was analyzed using GSEA software (www.broadinstitu
te.org/gsea/index.jsp), GEPAS (www.gepas.org) and POMELO
(http://pomelo2.bioinfo.cnio.es/) web tools. Our initial analysis
presented here focuses on early kinetics of gene expression in
skin and PB after alloBMT. Comparative profiles between pre-
transplant (baseline) and day 0 (post-conditioning) samples iden-
tified different gene sets in PB and in the skin; predominantly
cytokines and their signaling pathways, such as IL2, IL22BP,
IL3, IL4, IL5, IL7, IFNa, EPO, STAT3, ERK5, MAPK, in the
former, and apoptosis, cell cycle and growth (FAS, CDK4,
CDK6, CDKN1B, CDKN2C) in the latter. Gene set enrichment
analysis from day 0 to day +14-21 (engraftment) showed a higher
range of changes in PB (mainly cytokines and immunology gene
sets) than in the skin, which at this point included additional
gene sets from pathways from extracellular matrix and integrins.
This is the first report on a prospective and sequential examina-
tion of gene expression in paired PB and skin samples from
allogeneic BMT recipients. Our results suggest that the pathways
triggered after conditioning therapy and early after BMT differ
between PB and the skin. This finding provides novel insight
into the alloreactive phenomena occurring in humans, and bears
important implications for the identification of novel biomarkers
that may be more relevant to predict GVHD in patients’ target
organs.475
EFFECTIVE TREATMENT OF ACUTE GVHD AFTER HAPLOIDENTICAL BMT
WITH IN VITRO EXPANDED MURINE CD4+CD25+ REGULATORY T CELLS
Boeld, T.J.1, Spacenko, E.1, Eder, R.1, Weber, C.1, Lang-Schwarz, C.2,
Huber, E.2, Andreesen, R.1, Hoffmann, P.1, Edinger, M.1 1University
Hospital, Regensburg, Germany; 2University Hospital, Regensburg,
Germany
Graft-versus-host disease (GvHD) is a major complication after
allogeneic bone marrow transplantation (BMT). We and others
previously showed that the co-transplantation of large numbers of
donor-derived CD4+CD25+ regulatory T (Treg) cells protects
from lethal GvHD inmurine BMTmodels.We now tested, whether
Treg cells have also therapeutic efficacy. For this purpose, a haploi-
dentical GvHDmodel (BALB/c/CB6F1) was used and, in analogy
to potential clinical applications, donor Treg cells were expanded in
vitro. CD4+CD25highCD62L+ T cells were purified by FACS and
stimulated polyclonally using anti-CD3/CD28-coated beads. Cells
expanded on average 140-fold (627-fold, n 5 5) within 2 wks and
maintained high levels of FoxP3 expression (9662.3%, n 5 5) as
well as potent immunosuppressive activity in vitro. For the induction
of acute GvHDCB6F1 recipients were lethally irradiated and trans-
planted with 2.5x106 BM cells in combination with 5x106 spleno-
cytes. All animals developed severe GvHD by d11, as revealed by
an increase of the GvHD severity score (2.360.4 in GvHD animals
vs. 060 in BM controls, n 5 10-11) and by histological analyses of
the gut (score: 7.860.4 GvHD group vs. 0.260.2 BM controls,
p 5 0.046, n 5 3). When animals with acute GvHD were treated
with 5x106 in vitro expanded Treg cells on d11 after BMT, treated
and non-treated animals initially showed an identical increase of
their GvHD score. However, from d40 onwards the GvHD score
of mice that had received Treg cells decreased (4.160.6 vs. 6.060
in treated vs. non-treated mice, respectively, on d44, p 5 0.02) and
60% of these mice survived for 100d while all non-treated animals
died by d60 after BMT (p 5 0.014, n 5 10). Successfully treated
mice showed only mild histological signs of gut GvHD on d100 as
compared to non-treated animals with end-stage disease (score:
4.361 vs. 12.560.6 in treated vs. non-treated animals, p 5 0.006,
n5 4-6).Taken together, these results suggest that in vitro expanded
natural Treg cells may not only be effective for the prevention of
acute GvHD, but also for the treatment of acute gastrointestinal
GvHD after allogeneic BMT.476
A PILOT STUDY OF ONCE-DAILY MODIFIED RELEASE FORMULATION
TACROLIMUS HYDRATE (GRACEPTOR) AND PHARMACOKINETIC
EVALUATION IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANT
RECIPIENTS
Yano, S.1, Saito, T.1, Yokoyama, H.1, Machishima, T.1, Yahagi, Y.1,
Sugiyama, K.1, Ogasawara, Y.1, Kasama, K.1, Katsube, A.1, Usui, N.1,
Aiba, K.1, Mori, S.2 1Jikei University School of Medicine, Tokyo, Japan;
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Background:Graceptor is a once-daily modified release formula-
tion of tacrolimus. Not only it maintains its efficacy at the similar
level with the existing drug, Prograf, but also the once-daily ad-
ministration possibly contributes to reduce physical and mental
stress for patients. We investigated the efficacy and safety of the
once-daily administration of tacrolimus in patients who received
allogeneic hematopoietic stem cell transplant recipients from unre-
lated donors (UD-HSCT).
Methods: Patients received tacrolimus 0.03mg/kg intravenous by
continuous infusion, and administration was converted to oral at
a 1:3 or 4 ratios when the patient could tolerate oral medication.
Doses were modified to maintain whole-blood trough levels of
5-10 ng/ml. To analyze pharmacokinetics (PK) of tacrolimus.
Plasma concentration of tacrolimus was determined by ELISA.
Results: A total of 15 patients with hematological malignancies
(AML 6, ALL 3, MDS 3, CML 1, NHL 2) were enrolled. Median
age was 45 (23-65) years. Preparative regimens were myeloablative
(n5 8) or reduced intensity (n5 7), stem cell sources were bonemar-
row (BM) from HLA-matched unrelated donor (n 5 9), BM from
HLA DRB1 mismatched unrelated donor (n 5 2), or cord blood
(n5 4). Three out of 15 patients (20%) developed grade II-IV acute
GVHD, and 3 of 15 patients (20%) developed chronic GVHD. No
